Pros | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Among most bought funds within the category. | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | 3/8 | 2/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 7 Years | 12 Years | ||
Fund Size | 6162 Cr | 3963 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹500 Lumpsum ₹5000 | ||
Expense Ratio | 1.04% | 0.91% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 40 | 34 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.71%) Dr Reddy's Laboratories Ltd (9.47%) Divi's Laboratories Ltd (9.23%) Cipla Ltd (7.39%) Aurobindo Pharma Ltd (6.53%) | Sun Pharmaceuticals Industries Ltd (10.86%) Divi's Laboratories Ltd (6.81%) Max Healthcare Institute Ltd Ordinary Shares (6.12%) Cipla Ltd (4.81%) Lonza Group Ltd ADR (4.24%) | ||
No of Sectors | 3 | 3 | ||
Top 3 Sectors | Health (97.35%) Basic Materials (1.5%) Financial Services (1.15%) | Health (93.98%) Basic Materials (6.02%) Government (1.7%) | ||
Equity % | 95.88% | 96.15% | ||
Debt % | - | - | ||
P/E | 31.02 | 44.11 | ||
P/B | 4.22 | 6.33 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.85% | 0.4% | ||
3-Month Return | 4.81% | 3.02% | ||
6-Month Return | 16.1% | 9.69% | ||
1-Year Return | 4.86% | 4.39% | ||
3-Year Return | 30.54% | 27.55% | ||
5-Year Return | 21.58% | 21.17% |
Sharpe | 1.31 | 1.36 | ||
Alpha | 4.41 | 4.73 | ||
Beta | 0.94 | 0.84 | ||
Standard Deviation | 15.52 | 13.92 | ||
Information Ratio | 1.42 | 0.72 |
Description | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Dharmesh Kakkad,Sharmila D’mello | Tanmaya Desai |